Small molecules which activate Telomerase Reverse Transcriptase

Neuromagen Pharma is focused on developing a novel class of small molecules that activate Telomerase Reverse Transcriptase (TERT), an enzyme crucial for cellular longevity and protection against neurodegenerative diseases. TERT not only helps prevent telomere shortening, which leads to cellular senescence, but also exhibits neuroprotective properties that enhance cellular resilience against oxidative stress. The company’s lead compounds, referred to as AGS, have shown promising therapeutic effects in various preclinical models, including significant improvements in the survival of motor neurons and cognitive function in models of amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.

The therapeutic potential of Neuromagen's AGS compounds has been validated through extensive in vitro and in vivo studies. For instance, AGS-499 demonstrated the ability to delay the onset and progression of ALS in murine models, while also increasing neuronal survival in the presence of amyloid beta toxicity. Additionally, the compounds have been shown to reduce amyloid beta plaque burden in Alzheimer’s models, indicating their multifaceted role in combating neurodegenerative processes. Overall, Neuromagen Pharma's innovative approach aims to extend the lives of patients suffering from these debilitating conditions by targeting the underlying mechanisms of cellular aging and damage.

Israel

Neuromagen Pharma is an early-stage pharmaceutical company developing a new class of innovative small molecules which activate telomerase reverse transcriptase (TERT) – an enzyme which plays a major role in aging-related diseases and in cellular senescence. Neuromagen's pipeline includes drugs for neurodegenerative diseases such as ALS and Alzheimer's, type 1 diabetes, fertility, and cardiovascular diseases.

Neuromagen Pharma

Company Details